Core Viewpoint - The article emphasizes the optimistic outlook for the domestic and global development of energy medicine technology in China, particularly through the advancements made by the company Youmagic's subsidiary, Weimai Medical, which recently completed a Pre-C round of financing [1][4]. Financing and Investment - Weimai Medical secured several tens of millions of RMB in funding from the renowned investment institution SBI, which will be utilized for deepening core technology research, building clinical data systems, and enhancing international registration and compliance capabilities [1][4]. - SBI is recognized as a leading financial and investment group in Asia, focusing on long-term value and global perspectives in sectors like biomedicine and healthcare [1]. Technological Advancements - Weimai Medical is positioned as a platform company with capabilities in energy medicine, integrating research, development, production, and sales, thus creating a unique technological barrier through systematic innovation [2][4]. - The company has achieved breakthroughs in high-energy monopolar radiofrequency technology, enhancing the medical delivery experience to be more effective and comfortable, which is well-received by both doctors and consumers [2][4]. Market Position and Certification - The domestic high-end medical device market has been dominated by foreign brands, presenting a structural opportunity for domestic brands like Weimai Medical to break the monopoly [4]. - Weimai Medical's products have received dual certifications from China's NMPA and the US FDA, with clinical results showing a 100% improvement rate in wrinkles after three months and a 96.2% effect maintenance rate after six months, significantly outperforming similar imported devices [4]. Future Development and Global Expansion - With the completion of the Pre-C round financing, Weimai Medical will enhance its research and development in high-energy monopolar radiofrequency and related energy medicine technologies, while also deepening collaborations with top medical institutions [4][5]. - The company aims to build a more mature international team to connect with global research institutions and high-end medical partners, focusing on "technical cooperation + clinical co-construction" to foster academic exchange and commercial integration [5].